These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11863113)

  • 1. Fecal occult blood testing for colorectal cancer: a perspective.
    Barry MJ
    Ann Oncol; 2002 Jan; 13(1):61-4. PubMed ID: 11863113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal occult blood testing for colorectal cancer. Can we afford not to do this?
    Bond JH
    Gastroenterol Clin North Am; 1997 Mar; 26(1):57-70. PubMed ID: 9119440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing.
    Wong CK; Lam CL; Wan YF; Fong DY
    BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal occult blood and flexible sigmoidoscopy screening for colorectal cancer: modeling the impact on colonoscopy requirements and cancer detection rates.
    Olynyk JK; Platell CF; Collett JA
    J Gastroenterol Hepatol; 2001 Apr; 16(4):389-92. PubMed ID: 11354276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
    Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
    BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
    Solomon MJ; McLeod RS
    CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of screening for colorectal cancer.
    Telford JJ; Levy AR; Sambrook JC; Zou D; Enns RA
    CMAJ; 2010 Sep; 182(12):1307-13. PubMed ID: 20624866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimates of costs and effects of screening for colorectal cancer in the United States.
    Byers T; Gorsky R
    Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.
    Sobhani I; Alzahouri K; Ghout I; Charles DJ; Durand-Zaleski I
    Dis Colon Rectum; 2011 Jul; 54(7):876-86. PubMed ID: 21654256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.
    Vijan S; Hwang EW; Hofer TP; Hayward RA
    Am J Med; 2001 Dec; 111(8):593-601. PubMed ID: 11755501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flexible sigmoidoscopy versus fecal occult blood testing for colorectal cancer screening in asymptomatic individuals.
    Stern C
    Clin J Oncol Nurs; 2014 Aug; 18(4):471-2. PubMed ID: 25095304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic evaluation of screening for colorectal cancer: Case of Iran.
    Barouni M; Ghaderi H; Shahmoradi MK
    Clin Lab; 2013; 59(5-6):667-74. PubMed ID: 23865368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population screening for colorectal carcinoma with fecal-occult blood testing: are we sufficiently informed?
    Agrez MV; Coory M; Cockburn J
    Cancer; 1998 May; 82(10):1803-7. PubMed ID: 9587111
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.